Lineage Cell Therapeutics (LCTX) Cash & Equivalents Growth (3y) (2013 - 2026)
Lineage Cell Therapeutics (LCTX) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 13.29% |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.63% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -16.07% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.88% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 47.78% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 254.83 Mn | 192.11 Mn | 1.73 Mn | 43.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.10% |
| Dec 31, 2025 | 59.37% |
| Sep 30, 2025 | 9.19% |
| Jun 30, 2025 | -15.82% |
| Mar 31, 2025 | -15.03% |
| Dec 31, 2024 | -9.72% |
| Sep 30, 2024 | -23.01% |
| Jun 30, 2024 | -21.82% |
| Mar 31, 2024 | -8.14% |
| Dec 31, 2023 | -2.79% |
| Sep 30, 2023 | -1.13% |
| Jun 30, 2023 | 38.79% |
| Mar 31, 2023 | 16.26% |
| Dec 31, 2022 | 6.14% |
| Sep 30, 2022 | 19.88% |
| Jun 30, 2022 | 105.12% |
| Mar 31, 2022 | 63.04% |
| Dec 31, 2021 | 33.20% |
| Sep 30, 2021 | 46.18% |
| Jun 30, 2021 | 31.59% |